Intercept pharmaceuticals inc.
Intercept Pharmaceuticals Stock Forecast. All Analysts Top Analysts Stock Price Forecast. According to 8 stock analysts, the average 12-month stock price forecast for ICPT stock stock was $22.5, which predicted an increase of 18.42%. The lowest target was $14 and the highest was $54. On average, analysts rated ICPT stock stock as a hold.
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry.MORRISTOWN, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...Director. Mark Pruzanski, M.D. is one of our co-founders and has served as a member of our Board of Directors since inception in 2002. Dr. Pruzanski served as Intercept’s President and Chief Executive Officer until 2021. Dr. Pruzanski has over 20 years of experience in life sciences company management, venture capital and strategic consulting. Reprints. Adobe. I ntercept Pharmaceuticals, a firm whose treatment for a prevalent liver disease once made it the hottest stock in biotech, said Tuesday it would sell the company for less than $1 ...Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc. BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept ...
Mar 6, 2023 · March 6, 2023 at 5:59 AM · 17 min read. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) Q4 2022 Earnings Call Transcript March 2, 2023. Operator: Good day and thank you for standing by. Welcome to ...
MORRISTOWN, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the …MORRISTOWN, N.J., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug ...
EPS. Shares Outstanding. Intercept Pharmaceuticals, Inc. gross profit from 2013 to 2023. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services. Intercept Pharmaceuticals, Inc. Annual Gross Profit. (Millions of US $) 2022 ...Apr 27, 2023 · Intercept Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations (Unaudited) (In thousands, except per share data) Three Months Ended March 31, 2023 2022 Revenue: Product revenue, net $ 67,958 $ 59,146 Total revenue 67,958 59,146 Operating expenses: Cost of sales 222 223 Live Chat Inc. is a tool you can use to interact with customers or clients on the internet. More and more, consumers are demanding and expecting immediate help from the companies they approach. This application enables you to engage with cu...Director. Keith Gottesdiener, M.D. has served as a member of our Board of Directors since July 2016. Since July 2020, Dr. Gottesdiener has served as the President and Chief Executive Officer and as a director of Prime Medicine, Inc., a biopharmaceutical company based in Cambridge, Massachusetts. Prior to that, from October 2011 until March 2020 ...
Nov 8, 2023 · Following the completion of Alfasigma’s successful tender offer to purchase all outstanding shares of common stock of Intercept for USD 19.00 per share, net to the seller thereof in cash ...
Apr 13, 2023 · MORRISTOWN, N.J., April 13, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...
Intercept Pharmaceuticals Inc (Intercept) is a biopharmaceutical company that researches, develops, and commercializes treatments for non-viral, progressive liver diseases. It develops products using proprietary bile acid chemistry. The company’s lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist ... Follow. MORRISTOWN, N.J., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A.. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc.. Following the completion …May 19, 2023 · MORRISTOWN, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the outcome of the U.S. Food and Drug Administration (FDA) Gastrointestinal Drugs ... Cash on Hand. Long Term Debt. Total Liabilities. Share Holder Equity. Intercept Pharmaceuticals, Inc. total assets from 2013 to 2023. Total assets can be defined as the sum of all assets on a company's balance sheet. Intercept Pharmaceuticals, Inc. Annual Total Assets. (Millions of US $)
MORRISTOWN, N.J., July 07, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced positive topline results from a new interim analysis of its ongoing pivotal Phase 3 ...Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc. BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept ... Invisible Fence Inc. is a leading provider of innovative pet containment and lifestyle solutions. With over 40 years of experience, Invisible Fence Inc. has developed products that are designed to keep pets safe and secure in their own yard...BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc. Following the completion of Alfasigma’s ...NEW YORK, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has formally notified the European Medicines Agency (EMA) of its decision to withdraw its Marketing Authorization Application (MAA ...Intercept Pharmaceuticals, Inc.ICPT announced a restructuring program in the wake of the recent complete response letter (CRL) issued by the FDA to its new drug application (NDA) seeking approval ...Apr 13, 2023 · MORRISTOWN, N.J., April 13, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2023 financial results on Thursday, April 27, 2023, and provide an update on the commercial launch strategy for ...
Shares of Intercept Pharmaceuticals Inc. (ICPT) were set to soar Tuesday, after the biopharmaceutical company announced an agreement to be acquired by Italy's Alfasigma S.p.A in a deal that values ...When it comes to staying informed and up-to-date with the latest news, there are countless options available. One popular choice for many people is Apple News, a news aggregator developed by Apple Inc.
Nov 8, 2023 · Intercept Pharmaceuticals, Inc. --Alfasigma S.p.A. and Intercept Pharmaceuticals, Inc. announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned ... Find the latest press releases and official documents published by Intercept Pharmaceuticals, Inc. on MarketScreener. 1c3d5d21ecf5183126574.dO3e2DsrXc4NYbuyWVLp4XTyz_7wqtUICFlQOrE97XA.PqurgHZmP59mO4jlHz-4si28qrOTk4VxaTN9cuR-3QU7g-maY2Ec-DsH9gIntercept Pharmaceuticals, Inc. (Nasdaq – ICPT) Under the terms of the agreement, Intercept will be acquired by Alfasigma S.p.A (“Alfasigma”) for $19.00 per share in cash for each share of ...As pet owners, we want to keep our furry friends safe and secure. Invisible Fence Inc. has been providing pet owners with innovative solutions to keep their pets out of harm’s way for over 40 years. With their advanced technology, Invisible...MORRISTOWN, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the outcome of the U.S. Food and Drug Administration (FDA) Gastrointestinal Drugs ...Sep 26, 2023 · Reprints. Adobe. I ntercept Pharmaceuticals, a firm whose treatment for a prevalent liver disease once made it the hottest stock in biotech, said Tuesday it would sell the company for less than $1 ... For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. If you have any questions about this investigation, please contact: Jeffrey P. Campisi ...Nov 8, 2023 · Following the completion of Alfasigma’s successful tender offer to purchase all outstanding shares of common stock of Intercept for USD 19.00 per share, net to the seller thereof in cash ...
Cash on Hand. Long Term Debt. Total Liabilities. Share Holder Equity. Intercept Pharmaceuticals, Inc. total assets from 2013 to 2023. Total assets can be defined as the sum of all assets on a company's balance sheet. Intercept Pharmaceuticals, Inc. Annual Total Assets. (Millions of US $)
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic ...
Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases.MORRISTOWN, N.J., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...Director. Keith Gottesdiener, M.D. has served as a member of our Board of Directors since July 2016. Since July 2020, Dr. Gottesdiener has served as the President and Chief Executive Officer and as a director of Prime Medicine, Inc., a biopharmaceutical company based in Cambridge, Massachusetts. Prior to that, from October 2011 until March 2020 ...Intercept Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware. 22-3868459 (State or Other Jurisdiction of. Incorporation or Organization) (I.R.S. Employer. Identification No. ) 305 Madison Avenue, Morristown, NJ. 07960 (Address of Principal Executive Offices and Zip Code) (646) 747-1000Hayward Pool Products Inc has been a leader in the swimming pool industry for over 90 years. Founded in 1925, Hayward has been committed to providing innovative and high-quality products for residential and commercial pools.Intercept Pharmaceuticals (NASDAQ:ICPT) shareholders have endured a 83% loss from investing in the stock five years ago It is a pleasure to report that the Intercept Pharmaceuticals, Inc. ( NASDAQ ...Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. ( “Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma …Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry.
Selected Fourth Quarter and Full Year 2022 Financial Results. Intercept recognized $77.2 million in U.S. net sales in the fourth quarter 2022 as compared to $68.7 million in U.S. net sales in the ...Pipeline - Intercept Pharmaceuticals Home > Our Research > Pipeline Our Pipeline Our portfolio is based on novel scientific targets with the potential for therapeutic application …Intercept Pharmaceuticals, Inc. ICPT announced that the FDA has granted orphan drug designation for the fixed-dose combination of obeticholic acid (OCA) and bezafibrate, for the potential ...Instagram:https://instagram. collectors quarterssfyfnursing home reitsoptions vs forex trading Intercept Pharmaceuticals, Inc. is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Intercept Pharmaceuticals, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Intercept Pharmaceuticals, Inc. or its management.FXR is a nuclear receptor found in the liver, intestine, kidney, and adipose tissue. FXR regulates many biological processes, including: Bile acid metabolism. Inflammation. Fibrosis. Glucose metabolism. Lipid metabolism. In addition to their role in digestion and absorption, bile acids have been shown to bind and activate dedicated receptors ... barron's subscriberdavid blaine vegas Intercept Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware. 22-3868459 (State or Other Jurisdiction of. Incorporation or Organization) (I.R.S. Employer. Identification No. ) 305 Madison Avenue, Morristown, NJ. 07960 (Address of Principal Executive Offices and Zip Code) (646) 747-1000 fernando jorge Hayward Pool Products Inc is a leading manufacturer of high-quality pool equipment, including pumps, filters, heaters, and cleaners. If you’re lucky enough to own one of their products, it’s important to keep it in good condition to ensure ...Company profile page for Intercept Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact informationIntercept Pharmaceuticals, Inc. (“Intercept”) is a U.S.-based biopharmaceutical company focused on developing and commercialising novel therapeutics to treat progressive non-viral liver diseases. The acquisition includes the ex-U.S. rights to commercialise orphan drug Ocaliva® (obeticholic acid) for primary biliary cholangitis …